Log in to search using one of your social media accounts:

 

FDA approves Roche ’s Gazyva for previously untreated advanced follicular lymphoma
Roche announced today that the US Food and Drug Administration (FDA) approved Gazyva ® (obinutuzumab) in combination with chemotherapy, followed by Gazyva alone in those who responded, for people with previously untreated advanced follicular lymphoma (stage II bulky, III or IV). The approval is based on results from the phase III GALLIUM study, which showed superior progression-fre e survival (PFS) for patients who received this Gazyva-based regimen compared with those who received a Rituxan® (rituximab)-based regimen as an initial (first-line) therapy. Follicular lymphoma, the most common slow-growing (indolent) f...
Source: Roche Media News - November 17, 2017 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Gazyva for previously untreated advanced follicular lymphoma
Roche announced today that the US Food and Drug Administration (FDA) approved Gazyva ® (obinutuzumab) in combination with chemotherapy, followed by Gazyva alone in those who responded, for people with previously untreated advanced follicular lymphoma (stage II bulky, III or IV). The approval is based on results from the phase III GALLIUM study, which showed superior progression-fre e survival (PFS) for patients who received this Gazyva-based regimen compared with those who received a Rituxan® (rituximab)-based regimen as an initial (first-line) therapy. Follicular lymphoma, the most common slow-growing (indolent) f...
Source: Roche Investor Update - November 17, 2017 Category: Pharmaceuticals Source Type: news

Sandoz says new clinical data support two biosimilars
ZURICH (Reuters) - Novartis' generics division, Sandoz, said new immunology data from four clinical studies supported its proposed biosimilars adalimumab for treating psoriasis and cancer drug rituximab. (Source: Reuters: Health)
Source: Reuters: Health - November 14, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

MENTOR Results, New Trial Design Pitches at Kidney Week MENTOR Results, New Trial Design Pitches at Kidney Week
Findings from a randomized comparison of rituximab and cyclosporine for membranous nephropathy will be released here at Kidney Week, along with innovative trial design ideas for the future.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 25, 2017 Category: Consumer Health News Tags: Nephrology News Source Type: news

Rituximab Aids in IgA Vasculitis (CME/CE)
(MedPage Today) -- Effective in refractory cases of this rare disease, small study suggests (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - October 6, 2017 Category: Primary Care Source Type: news

PFS Up With Obinutuzumab - Based Tx in Follicular Lymphoma
Induction, maintenance treatment with obinutuzumab - based chemo beats rituximab (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - October 5, 2017 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Journal, Source Type: news

Obinutuzumab vs Rituximab in FL:'Too Close to Call'Obinutuzumab vs Rituximab in FL:'Too Close to Call '
Obinutuzumab for induction and maintenance provides significantly higher PFS than rituximab, the current standard of care for follicular lymphoma (FL). But an editorial cautions it's too soon to tell.Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 4, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Posttransplant MCL: Is There a New Therapeutic Standard? (CME/CE)
(MedPage Today) -- Study supports long-term rituximab maintenance as standard care (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 3, 2017 Category: Hematology Source Type: news

Adding Rituxan to treatment may extend survival for lymphoma patients: Study
Long-term treatment with the drug rituximab, or Rituxan, may extend the lives of some patients with a rare form of blood cancer, a new clinical trial finds. (Source: Health News - UPI.com)
Source: Health News - UPI.com - September 28, 2017 Category: Consumer Health News Source Type: news

Adding Rituximab to Standard Care May Prolong Lymphoma Survival
WEDNESDAY, Sept. 27, 2017 -- Long-term treatment with the drug rituximab (Rituxan) may extend the lives of some patients with a rare form of blood cancer, a new clinical trial finds. The disease, known as mantle-cell lymphoma, is generally... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 27, 2017 Category: General Medicine Source Type: news

Adding Drug to Standard Care May Prolong Lymphoma Survival
WEDNESDAY, Sept. 27, 2017 -- Long-term treatment with the drug rituximab (Rituxan) may extend the lives of some patients with a rare form of blood cancer, a new clinical trial finds. The disease, known as mantle-cell lymphoma, is generally... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 27, 2017 Category: General Medicine Source Type: news

Phase III data showed that Venclexta/Venclyxto plus MabThera/Rituxan helped people with previously treated chronic lymphocytic leukaemia live longer without their disease worsening compared to bendamustine plus MabThera/Rituxan
Roche announced today that the phase III MURANO study, which evaluated Venclexta ®/Venclyxto® (venetoclax) in combination with MabThera®/Rituxan® (rituximab) in people with relapsed or refractory chronic lymphocytic leukaemia (CLL), met its primary endpoint and showed a statistically significant improvement in the time people lived without their disease progressing (progress ion-free survival [PFS] as assessed by investigator) when treated with Venclexta/Venclyxto plus MabThera/Rituxan compared to bendamustine plus Mabthera/Rituxan. (Source: Roche Media News)
Source: Roche Media News - September 18, 2017 Category: Pharmaceuticals Source Type: news

Phase III data showed that Venclexta/Venclyxto plus MabThera/Rituxan helped people with previously treated chronic lymphocytic leukaemia live longer without their disease worsening compared to bendamustine plus MabThera/Rituxan
Roche announced today that the phase III MURANO study, which evaluated Venclexta ®/Venclyxto® (venetoclax) in combination with MabThera®/Rituxan® (rituximab) in people with relapsed or refractory chronic lymphocytic leukaemia (CLL), met its primary endpoint and showed a statistically significant improvement in the time people lived without their disease progressing (progress ion-free survival [PFS] as assessed by investigator) when treated with Venclexta/Venclyxto plus MabThera/Rituxan compared to bendamustine plus Mabthera/Rituxan. (Source: Roche Investor Update)
Source: Roche Investor Update - September 18, 2017 Category: Pharmaceuticals Source Type: news

Novartis says biosimilar rituximab accepted for review by FDA
ZURICH (Reuters) - Novartis AG said on Tuesday its biosimilar rituximab to treat blood cancers and immunological diseases such as rheumatoid arthritis was accepted for review by the U.S. Food and Drug Administration (FDA). (Source: Reuters: Health)
Source: Reuters: Health - September 12, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Study explains why myasthenia patients relapse after treatment
A new Yale-led study helps explain why some myasthenia gravis (MG) patients relapse after initially responding to a drug called rituximab. (Source: Yale Science and Health News)
Source: Yale Science and Health News - September 7, 2017 Category: Universities & Medical Training Source Type: news

In Utero Rituximab Exposure Linked to Sepsis in Preemie In Utero Rituximab Exposure Linked to Sepsis in Preemie
Infants born to mothers treated with rituximab, especially those born preterm, should be monitored closely for signs of infection, advise clinicians from Boston Children's Hospital in a paper online today in Pediatrics.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - August 3, 2017 Category: Intensive Care Tags: Pediatrics News Source Type: news

Rituximab Promising for RA Lung Disease (CME/CE)
(MedPage Today) -- Findings are reassuring for often lethal disease manifestation (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - July 30, 2017 Category: Geriatrics Source Type: news

Rituximab Biosimilars Shown to Be Safe and Effective Rituximab Biosimilars Shown to Be Safe and Effective
Two randomized trials confirm that two new biosimilars that have recently been introduced in Europe are efficacious and comparable to the reference product. Other biosimilars are on the way.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 28, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Roche, Emcure may end pact to make 2 blockbuster drugs
Emcure is still the distributor for those two drugs in India. Roche had handed out the manufacturing and marketing of trastuzumab and rituximab to Pune-based Emcure. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 24, 2017 Category: Pharmaceuticals Source Type: news

Refractory RA Yields to Rituximab (CME/CE)
(MedPage Today) -- All patient-reported outcomes showed improvements at 1 year (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - July 21, 2017 Category: Geriatrics Source Type: news

B-Cell Biomarkers May Guide Treatment of SLE (CME/CE)
(MedPage Today) -- Complete depletion of B cells is predictor of response to rituximab (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - July 18, 2017 Category: Consumer Health News Source Type: news

Novartis unit Alcon posts modest Q2 gain
(Reuters) — Long-suffering Novartis (NYSE:NVS) unit Alcon‘s sales growth accelerated in the second quarter, boosting options for the business including a possible disposal, CEO Joe Jimenez said today. The eye care subsidiary’s sales rose 1% to $1.5 billion, including intraocular lens revenues, which grew for the first time in the second quarter since 2014. Spending continued to promote products with eye surgeons, resulting in a $19 million operating loss. Novartis has been reviewing Alcon for a possible disposal, with an update slated for this year. All options are under consideration, Jimenez reiter...
Source: Mass Device - July 18, 2017 Category: Medical Devices Authors: Brad Perriello Tags: MassDevice Earnings Roundup Mergers & Acquisitions Optical/Ophthalmic Wall Street Beat Alcon Novartis Source Type: news

High-Dose Chemotherapy Plus Transplant Not Recommended for DLBCL
Patients with high-risk diffuse large B-cell lymphoma had a reduced risk of treatment failure, but no survival improvement, with an abbreviated course of rituximab-dose-dense chemotherapy plus high-dose chemotherapy and transplant compared with a full course of chemotherapy. (Source: CancerNetwork)
Source: CancerNetwork - July 13, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Leukemia & Lymphoma News Source Type: news

Medical News Today: Human antibody bolsters cancer drug performance
Some patients do not respond to the cancer drug rituximab, but breaking research finds that the addition of a human antibody reduces this resistance. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 1, 2017 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Roche ’s polatuzumab vedotin receives priority medicines scheme (PRIME) designation for treatment of the most common form of aggressive lymphoma
Roche today announced that the European Medicines Agency (EMA) has granted PRIME (PRIority MEdicines) designation for the company ’s investigational medicine polatuzumab vedotin in combination with MabThera® (rituximab) and bendamustine for the treatment of people with relapsed or refractory diffuse large B cell lymphoma (DLBCL), the most common aggressive form of non-Hodgkin lymphoma. (Source: Roche Investor Update)
Source: Roche Investor Update - June 30, 2017 Category: Pharmaceuticals Source Type: news

Rituxan Hycela (Rituximab And Hyaluronidase Human Injection) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 29, 2017 Category: Drugs & Pharmacology Source Type: news

New antibody appears to re-activate immune system in cancer therapy
(Duke University Medical Center) Adding an investigational antibody to the chemotherapy rituximab appears to restore its cancer-killing properties in certain leukemia patients with a natural resistance to the drug, according to a small, proof-of-concept study by Duke Cancer Institute researchers. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 28, 2017 Category: Cancer & Oncology Source Type: news

FDA Approves More Convenient Form of Roche Blood Cancer Drug FDA Approves More Convenient Form of Roche Blood Cancer Drug
U.S. health regulators on Thursday approved a new formulation of Roche's big-selling cancer drug Rituxan (rituximab) for three common types of blood cancers that allows for relatively quick administration via injection under the skin in place of a lengthy intravenous infusion, the company said.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 23, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Rituximab Biosimilar Shows Clinical Equivalence (CME/CE)
(MedPage Today) -- Multicenter study compared both European and U.S. rituximab originators (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - June 23, 2017 Category: Geriatrics Source Type: news

FDA approves Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection in certain blood cancers
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) approved Rituxan Hycela™ (rituximab and hyaluronidase human) for subcutaneous (under the skin) injection, for the treatment of adults with the following blood cancers: previously untreated and relapsed or refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma (DLBCL), and previously untreated and previously treated chronic lymphocytic leukaemia (CLL). (Source: World Pharma News)
Source: World Pharma News - June 23, 2017 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

FDA approves Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection in certain blood cancers
Roche announced today that the US Food and Drug Administration (FDA) approved Rituxan Hycela ™ (rituximab and hyaluronidase human) for subcutaneous (under the skin) injection, for the treatment of adults with the following blood cancers: previously untreated and relapsed or refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma (DLBCL), and previously untreated and previously treated chronic lymphocytic leukaemia (CLL). (Source: Roche Media News)
Source: Roche Media News - June 23, 2017 Category: Pharmaceuticals Source Type: news

FDA approves Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection in certain blood cancers
Roche announced today that the US Food and Drug Administration (FDA) approved Rituxan Hycela ™ (rituximab and hyaluronidase human) for subcutaneous (under the skin) injection, for the treatment of adults with the following blood cancers: previously untreated and relapsed or refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma (DLBCL), and previously untreated and previously treated chronic lymphocytic leukaemia (CLL). (Source: Roche Investor Update)
Source: Roche Investor Update - June 23, 2017 Category: Pharmaceuticals Source Type: news

FDA Approves Rituxan Hycela (rituximab and hyaluronidase human) for Subcutaneous Injection in Certain Blood Cancers
South San Francisco, CA -- June 22, 2017 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) approved Rituxan Hycela (rituximab and hyaluronidase human) for... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 22, 2017 Category: Drugs & Pharmacology Source Type: news

FDA approves more convenient form of Roche blood cancer drug
(Reuters) - U.S. health regulators on Thursday approved a new formulation of Roche's big-selling cancer drug Rituxan for three common types of blood cancers that allows for relatively quick administration via injection under the skin in place of a lengthy intravenous infusion, the company said. (Source: Reuters: Health)
Source: Reuters: Health - June 22, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

EC approves Sandoz ’s Rixathon for blood cancer and immunological diseases
Novartis division Sandoz ’s Rixathon (biosimilar rituximab) has received approval from the European Commission (EC) to treat blood cancers and immunological diseases in Europe. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - June 19, 2017 Category: Pharmaceuticals Source Type: news

Novartis throws down gauntlet to Roche with Rituxan copy
ZURICH (Reuters) - Switzerland's Novartis increased pressure on Roche's ageing stable of big-selling drugs on Monday by becoming the latest company to win European approval for a cut-price version of Rituxan for blood cancer and immunological diseases. (Source: Reuters: Health)
Source: Reuters: Health - June 19, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Novartis wins European approval for biosimilar version of Roche's MabThera
ZURICH (Reuters) - Swiss drugmaker Novartis on Monday said it had won European approval for its biosimilar version of Roche's blockbuster Rituxan as the crosstown rivals go head-to-head on a drug to treat blood cancers and immunological diseases. (Source: Reuters: Health)
Source: Reuters: Health - June 19, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

In Lymphoma, Best Partner With Rituximab Still in Question In Lymphoma, Best Partner With Rituximab Still in Question
Results from the StiL and BRIGHT studies confirm the long-term benefits of rituximab, but the optimal chemotherapy partner is still in question.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 15, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Truxima (rituximab) for the Treatment of Cancer
ruxima ™ (rituximab) is the first biosimilar monoclonal antibody (mAb) approved for the treatment of haematological cancers, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukaemia, and rheumatoid arthritis, as well… (Source: Drug Development Technology)
Source: Drug Development Technology - June 8, 2017 Category: Pharmaceuticals Source Type: news

Three More Biosimilar Rituximab Products in Europe Three More Biosimilar Rituximab Products in Europe
More biosimilar rituximab products are coming to Europe, bringing hope of lower prices.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 19, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

Subcutaneous Rituximab Safe, Effective for Follicular Lymphoma Subcutaneous Rituximab Safe, Effective for Follicular Lymphoma
Subcutaneous and intravenous rituximab offer similar safety and efficacy for first-line treatment of patients with follicular lymphoma, according to results from the open-label SABRINA trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 16, 2017 Category: Consumer Health News Tags: Pharmacist News Source Type: news

Reassessment of Anti-CD20 Therapy in Lymphoid Malignancies: Impact, Limitations, and New Directions
This review will highlight the survival impact that rituximab therapy has had on major lymphoid malignancies, such as diffuse large B-cell lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, and mantle cell lymphoma. We will also discuss alternative anti-CD20 monoclonal antibodies. (Source: CancerNetwork)
Source: CancerNetwork - May 15, 2017 Category: Cancer & Oncology Authors: Jonathan W. Friedberg, MD, MMSc Patrick M. Reagan, MD Tags: Hematologic Malignancies Leukemia & Lymphoma Oncology Journal Review Article Source Type: news

Biosimilar Rutiximabs, and Inotuzumab, Coming to Europe Biosimilar Rutiximabs, and Inotuzumab, Coming to Europe
Two biosimilar rituximab products have been recommended for approval in Europe, as has inotuzumab ozogamicin for acute lymphoblastic leukemia.International Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 24, 2017 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA advisory committee unanimously recommends approval of Roche ’s subcutaneous rituximab for certain blood cancers
Roche announced today that the U.S. Food and Drug Administration ’s (FDA) Oncologic Drugs Advisory Committee (ODAC) voted unanimously (11 to 0) that the benefit-risk of rituximab/hyaluronidase for subcutaneous (under the skin) injection was favourable for the treatment of certain blood cancers, which include: previously untreated follicular lymphoma, previously untreated diffuse large B-cell lymphoma (DLBCL), relapsed or refractory low grade or follicular lymphoma, and previously untreated and relapsed or refractory chronic lymphocytic leukemia (CLL). (Source: Roche Investor Update)
Source: Roche Investor Update - March 30, 2017 Category: Pharmaceuticals Source Type: news

FDA grants breakthrough therapy designation for MabThera/Rituxan (rituximab) in pemphigus vulgaris
Roche announced today that the US Food and Drug Administration (FDA) has granted breakthrough therapy designation status to MabThera/Rituxan ® (rituximab) for pemphigus vulgaris, a rare, serious and life-threatening condition characterised by progressive painful blistering of the skin and mucous membranes. (Source: Roche Investor Update)
Source: Roche Investor Update - March 24, 2017 Category: Pharmaceuticals Source Type: news

Escalated BEACOPP Plus Rituximab in Advanced Hodgkin Lymphoma Fails to Improve Outcomes
Adding rituximab to an escalated regimen of BEACOPP did not improve progression-free survival in patients with advanced-stage Hodgkin lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - March 11, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Leukemia & Lymphoma News Source Type: news

Rituximab in the Treatment of Inflammatory Myopathies Rituximab in the Treatment of Inflammatory Myopathies
Get up-to-date on what there is to know about the use of rituximab therapy in the management of myositis.Rheumatology (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - March 2, 2017 Category: Allergy & Immunology Tags: Rheumatology Journal Article Source Type: news

Europe ready to embrace first copies of biotech cancer drugs
LONDON (Reuters) - Treatment with two important cancer drugs is about to get much cheaper in Europe with a cut-price copy of Roche's blood cancer drug Rituxan likely to hit the market imminently followed by a rival to its breast cancer medicine Herceptin. (Source: Reuters: Health)
Source: Reuters: Health - February 15, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Serum IL-33 for Predicting Response to Rituximab in RA Serum IL-33 for Predicting Response to Rituximab in RA
Serum interleukin-33 shows promise as a potential new biomarker for predicting treatment response to rituximab.Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 15, 2017 Category: Consumer Health News Tags: Orthopaedics Journal Article Source Type: news

Roche denies rumors it will shop diabetes unit, earnings
Roche (PINK:RHHBY) denied rumors that it was considering selling its diabetes unit today, saying that it is “committed” to the business. The company also predicted that competition and spending on new drugs would stall its margin growth in 2017, as patents expire for its blockbuster medications. The Swiss drugmaker’s 3 top-selling cancer drugs, Rituxan, Herceptin and Avastin, bring in annual revenue of more than 20 billion Swiss francs, Reuters reported, and they face incoming competition from biosimilar copies. The 1st copies of Rituxan and Herceptin could hit the European market later thi...
Source: Mass Device - February 1, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Diabetes MassDevice Earnings Roundup Wall Street Beat Roche Roche Diabetes Care Source Type: news